Synthetic Lethal Co-Mutations in DNA Damage Response Pathways Predict Response to Immunotherapy in Pan-Cancer
Our study identified SL co-mutations in the DDR pathway as promising biomarkers for ICI efficacy. Specifically, the <i>TP53-ATM</i> co-mutation status can be applied in identifying ICI-responsive patients. SL co-mutations in DDR pathways correlate with modification of the tumor immune microenvironment, shaping a favorable niche for ICIs to stimulate immune responses.
Authors
- Lincheng Zhang (ORCID: https://orcid.org/0000-0002-2160-3420)
- Fengcai Wen
- Rong Qiao (ORCID: https://orcid.org/0009-0001-3668-0162)
- Yan Zhou (ORCID: https://orcid.org/0000-0002-5366-3620)
- Yue Wang (ORCID: https://orcid.org/0000-0003-3372-0226)
- Yao Zhang (ORCID: https://orcid.org/0000-0002-6223-422X)
- Wei Nie (ORCID: https://orcid.org/0000-0001-6878-7936)
- Miao Liu (ORCID: https://orcid.org/0009-0004-4235-9000)
- Huawei Du
- Huiping Qiang
- Hua Zhong (ORCID: https://orcid.org/0000-0003-3097-5717)
Institutions
- Shanghai Jiao Tong University (CN)
- Shanghai Chest Hospital (CN)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1200/po-25-00035
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09